Deutsche Bank Maintains Hold, $62 Target on Quest Diagnostics

Deutsche Bank reiterates its Hold rating and $62 target price on Quest Diagnostics

as the company posts solid Q4 results and guides positively to 2012 EPS. Deutsche Bank says, "DGX reported Q4 adjusted EPS of $1.15 (excluding $0.08 of tax benefits) vs. Factset consensus of $1.06 and DBe of $1.11. Adjusted EPS exclude $0.04 of restructuring and CEO succession costs. ... 2012 EPS outlook may appear light, but it seems like guidance doesn't include much buyback. This seems like a logical and conservative starting point for the company given that a new CEO will have to inherit this guidance." DGX closed at $56.50 a share on Monday.